iPCE 120
Alternative Names: iPCE-120Latest Information Update: 08 Mar 2024
At a glance
- Originator Cello Therapeutics
- Class Antineoplastics; Cancer vaccines; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jan 2024 Preclinical trials in Solid tumours in USA (Parenteral) (Cello Therapeutics pipeline, January 2024)
- 30 Aug 2022 Cello therapeutics has patent protection for membrane encapsulated nanoparticles and method of use in China, Canada, Denmark, Europe, Japan, Spain and Taiwan
- 24 May 2012 Cello therapeutics has patent pending for membrane encapsulated nanoparticles and method of use in USA, Hong kong and the World